A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.

See also
Status	Clinical Trial	Phase
Completed	`NCT06277752` - A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)	Phase 1
Completed	`NCT04587544` - The Relationship Between Cold Water Immersion and the Progression in Gout Arthritis	N/A
Not yet recruiting	`NCT05678049` - Evaluation and Characterisation of Microplastics and Nanoplastics in Joint Synovial Liquid
Recruiting	`NCT05744297` - NLRP3 Inflammasome Activation Among Patients During Acute Gout Flares

See also

Status

Clinical Trial

Phase

Completed

NCT06277752 - A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

Phase 1

Completed

NCT04587544 - The Relationship Between Cold Water Immersion and the Progression in Gout Arthritis

N/A

Not yet recruiting

NCT05678049 - Evaluation and Characterisation of Microplastics and Nanoplastics in Joint Synovial Liquid

Recruiting

NCT05744297 - NLRP3 Inflammasome Activation Among Patients During Acute Gout Flares

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT06270225
Study type	Interventional
Source	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Contact	Qinghong Zhou, MD
Phone	+86 18911301578
Email	zhouqinghong@3sbio.com
Status	Recruiting
Phase	Phase 2
Start date	March 30, 2024
Completion date	December 2024

A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms